The ArteraAI prostate test uses artificial intelligence and biomarkers to predict if standard hormone therapy will be ...

Insiders tell CNN the FDA’s AI is “hallucinating” studies and can’t access key documents. Agency leaders insist the AI is ...

Digital transformation in healthcare accelerates adoption of AI-enabled monitoring solutions across global marketsDelray ...

There is an immediate need for a new, agile process that helps everyday people find safe and trustworthy mental health AI ...

Signos announced today that it launched its FDA-cleared over-the-counter glucose monitoring system for weight management.

Walmart recalls shrimp in 13 states after FDA finds radioactive contamination. OpenAI challenger Manus hits $90M revenue run ...

The approval of ArteraAI Prostate by the FDA as a software as a medical device (SaMD) means it can now be used at the point ...

Nerveblox, the ultrasound AI for regional anaesthesia receives US FDA 510(k) clearance: Ankara Wednesday, August 20, 2025, 15:00 Hrs [IST] Nerveblox, an AI software solution by Sm ...

The rally in the market came as the approval made PAPZIMEOS the first and only FDA-approved therapy for adult RRP patients.

The FDA’s De Novo authorization for the tool establishes a new product code category for future AI-powered digital pathology risk-stratification tools.

Recent reports highlight uncertainty about pharmaceutical tariffs, an error-prone AI tool in use at the FDA, and research funding in jeopardy.

Key Points Spectral Ai completed its De Novo application submission to the FDA for the DeepView System in June 2025, marking a major regulatory milestone. Revenue for the quarter declined 32.0% year ...